APP and Alzheimer disease: Moreover, chronic administration of the TRPA1 channel inhibitor HC030031 to the APP/PS1-21 mice promoted the compaction of amyloid fibrils into plaques, reduced plaques’ toxic effect and prevented spatial working memory defects in these mice, suggesting that chronic treatment with the TRPA1 inhibitor has a strong beneficial effect on Alzheimer’s disease progression at multiple levels [63].